Moderna's 6-month Review Of COVID-19 Vaccine Post Dose 2 Shows More Than 90% Efficacy

Moderna's 6-month Review Of COVID-19 Vaccine Post Dose 2 Shows More Than 90% Efficacy

RTTNews

Published

Moderna, Inc. announced that updated cases in its trial show its COVID-19 Vaccine (mRNA-1273) is greater than 90% effective against all cases of COVID-19, with around 6 months median follow-up post-dose 2. The new data from the Phase 3 COVE Study also shows that the vaccine is greater than 95% effective against severe cases of COVID-19.

Full Article